Noah Labs Vox nabs FDA breakthrough for heart monitoring

Using voice as a biomarker for cardiac health is a compelling shift toward zero-friction, software-only diagnostics. Replacing invasive implants with a 5-second smartphone recording drastically lowers the barrier to daily remote patient monitoring. The algorithm was trained on over 3 million samples and validated at major institutions like the Mayo Clinic, highlighting the diagnostic power of speech analysis. FDA breakthrough status accelerates its U.S. clinical trials and path to commercialization, complementing its expected EU approval by mid-2026.